Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus
- 26 April 2016
- journal article
- research article
- Published by Elsevier BV in Diabetes Research and Clinical Practice
- Vol. 116, 171-182
- https://doi.org/10.1016/j.diabres.2016.04.012
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trialDiabetes and Vascular Disease Research, 2013
- Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes MellitusThe American Journal of Cardiology, 2012
- Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and ChemotaxisCirculation, 2011
- Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide studyEuropean Heart Journal, 2011
- Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?Heart, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial InfarctionThe New England Journal of Medicine, 1998
- Predictors of Stroke in Middle-Aged Patients With Non–Insulin-Dependent DiabetesStroke, 1996
- Hyperglycemie and Microvascular and Macrovascular Disease in DiabetesDiabetes Care, 1995